1. Home
  2. APD vs ALNY Comparison

APD vs ALNY Comparison

Compare APD & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APD
  • ALNY
  • Stock Information
  • Founded
  • APD 1940
  • ALNY 2002
  • Country
  • APD United States
  • ALNY United States
  • Employees
  • APD N/A
  • ALNY N/A
  • Industry
  • APD Major Chemicals
  • ALNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • APD Industrials
  • ALNY Health Care
  • Exchange
  • APD Nasdaq
  • ALNY Nasdaq
  • Market Cap
  • APD 65.2B
  • ALNY 59.1B
  • IPO Year
  • APD 1987
  • ALNY 2004
  • Fundamental
  • Price
  • APD $257.49
  • ALNY $470.45
  • Analyst Decision
  • APD Buy
  • ALNY Strong Buy
  • Analyst Count
  • APD 12
  • ALNY 28
  • Target Price
  • APD $325.45
  • ALNY $457.37
  • AVG Volume (30 Days)
  • APD 1.2M
  • ALNY 1.1M
  • Earning Date
  • APD 11-06-2025
  • ALNY 10-30-2025
  • Dividend Yield
  • APD 2.78%
  • ALNY N/A
  • EPS Growth
  • APD N/A
  • ALNY N/A
  • EPS
  • APD 6.95
  • ALNY N/A
  • Revenue
  • APD $12,057,900,000.00
  • ALNY $2,461,963,000.00
  • Revenue This Year
  • APD $0.40
  • ALNY $59.55
  • Revenue Next Year
  • APD $4.59
  • ALNY $40.90
  • P/E Ratio
  • APD $37.02
  • ALNY N/A
  • Revenue Growth
  • APD N/A
  • ALNY 5.01
  • 52 Week Low
  • APD $243.69
  • ALNY $205.87
  • 52 Week High
  • APD $341.14
  • ALNY $485.00
  • Technical
  • Relative Strength Index (RSI)
  • APD 29.66
  • ALNY 64.58
  • Support Level
  • APD $257.73
  • ALNY $449.88
  • Resistance Level
  • APD $266.10
  • ALNY $464.46
  • Average True Range (ATR)
  • APD 5.60
  • ALNY 13.42
  • MACD
  • APD -0.87
  • ALNY 0.05
  • Stochastic Oscillator
  • APD 10.57
  • ALNY 65.31

About APD Air Products and Chemicals Inc.

Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $12.1 billion in revenue in fiscal 2024.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: